Low Molecular Weight Heparins: Structural Differentiation by Bidimensional Nuclear Magnetic Resonance Spectroscopy

ABSTRACT

Individual low molecular weight heparins (LMWHs) exhibit distinct pharmacological and biochemical profiles because of manufacturing differences. Correlation of biological properties with particular structural motifs is a major challenge in the design of new LMWHs as well as in the development of generic versions of proprietary LMWHs. Two-dimensional nuclear magnetic resonance (NMR) spectroscopy permits identification and quantification of structural peculiarities of LMWH preparations. In this article, heteronuclear single quantum coherence spectroscopy, previously used to determine variously substituted monosaccharide components of heparan sulfate (HS) and HS-like glycosaminoglycan mimics, has been applied to the structural characterization of three commercially available LMWHs (enoxaparin, dalteparin, and tinzaparin). Relevant residues belonging to the parent heparin, as well as minor residues generated by each depolymerization procedure, have been characterized and quantified. The use of a high-sensitivity NMR spectrometer (600 MHz equipped with cryoprobe) allowed the accurate quantification of residues with sensitivity better than 1 to 2%.

Low molecular weight heparins (LMWHs) - nuclear magnetic resonance (NMR) - heteronuclear single quantum coherence (HSQC) - quantitative analysis - sulfation pattern

REFERENCES

• 1 Hoppensteadt D, Iqbal O, Fareed J. Basic and clinical differences of heparin and low molecular weight heparin treatment. In: Garg HG, Linhardt RJ, Hales CA Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd 2006: 583-606
• 2 Lever R, Page C P. Novel drug development opportunities for heparin.  Nat Rev Drug Discov. 2002;  1 140-148
• 3 Casu B. Structure and active domains of heparin. In: Garg HG, Linhardt RJ, Hales CA Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd 2006: 1-28
• 4 de Kort M, Buijsman R C, van Boeckel C AA. Synthetic heparin derivatives as new anticoagulant drugs.  Drug Discov Today. 2005;  10 769-779
• 5 van Boeckel C AA, Petiou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics.  Angew Chem Int Ed Engl. 1993;  32 1671-1690
• 6 Belzac K J, Dafforn T R, Petitou M et al.. The effect of a reducing-end extension on pentasaccharide binding by antithrombin.  J Biol Chem. 2000;  275 8733-8741
• 7 Guerrini M, Guglieri S, Beccati D et al.. Conformational transitions induced in heparin octasaccharides by binding with antithrombin III.  Biochem J. 2006;  399 191-198
• 8 Hirsh J, Warkentin T, Raschke R et al.. Heparin and low molecular weight heparin. Mechanism of action, pharmacokinetics, dosing consideration, monitoring safety and efficacy.  Chest. 1998;  114 489S-501S
• 9 Capila I, Guany N S, Shriver Z, Venkataraman G. Methods for structural analysis of heparin and heparin sulfate. In: Garg HG, Linhardt RJ, Hales CA Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd 2006
• 10 Guerrini M, Bisio A, Torri G. Combined quantitative ¹H and ¹³C-NMR spectroscopy for characterization of heparin preparations.  Semin Thromb Hemost. 2001;  27 473-48
• 11 Casu B, Guerrini M, Naggi A et al.. Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy.  Arzneim Forsch/Drug Res. 1996;  46 472-477
• 12 Guerrini M, Naggi A, Guglieri S et al.. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy.  Anal Biochem. 2005;  337 35-47
• 13 Lormeau J-C, Petitou M, Choaj J. Oligosaccharides having anti Xa activity and pharmaceutical compositions containing them. US patent #RE 35770.  1998; 
• 14 Huckerby T N, Sanderson P N, Nieduszynski A NMR. Studies of the disulphated disaccharide obtained by degradation of bovine lung heparin with nitrous acid.  Carbohydr Res. 1985;  138 199-206
• 15 Mourier P, Viskov C US. , Patent 2005/0119477 A1; Chem Abstr 142:89363
• 16 Mascellani G, Guerrini M, Torri G et al.. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydrohydro-β-D-glucosamine or N-sulfated 1,6-an β-D-mannosamine residues.  Carbohydr Res. 2007;  342 835-842
• 17 Černy I, Buděšinsky M, Trnka T, Černy M. Preparation of 2-amino-1,6-anhydro-2,3-dideoxy-β-D-arabino-hexopyranose. ¹H- and ¹³C-n.m.r. spectra of deoxy derivatives of 2-amino-1,6-anhydro-2-deoxy-D-glucose and 2-amino-1,6-anhydro-2-deoxy-D-mannose.  Carbohydr Res. 1984;  130 103-114
• 18 Robinson H C, Horner A A, Hook A et al.. A proteoglycan form of heparin and its degradation to single-chain molecules.  J Biol Chem. 1978;  253 6687-6693
• 19 Chuang W L, McAllister H, Rabenstein D. Hexasaccharides from the istamine-modified depolymerization of porcine intestinal mucosal heparin.  Carbohydr Res. 2002;  337 935-945
• 20 Yates E A, Santini F, Guerrini M et al.. ¹H and ¹³C NMR spectral assignment of the major sequences of twelve systematically modified heparin derivatives.  Carbohydr Res. 1996;  294 15-27
• 21 Yamada S, Watanabe M, Sugahara K. Conversion of N-sulfated glucosamine to N-sulfated mannosamine in an unsaturated heparin disaccharide by non-enzymatic, base-catalyzed C-2 epimerization during enzymatic oligosaccharide preparation.  Carbohydr Res. 1998;  309 261-268
• 22 Toida T E, Viahov I R, Smith A E et al.. C-2 epimerization of N-acetylglucosamine in an oligosaccharide derived from heparan sulfate.  Carbohydr Chem. 1996;  15 351-360
• 23 Yamada S, Murakami T, Tsuda H et al.. Isolation of the porcine heparin tetrasaccharides with glucuronate 2-O-sulfate.  J Biol Chem. 1995;  270 8696-8705
• 24 Rej R N, Perlin A S. Base-catalyzed conversion of the α-L-iduronic acid 2-sulfate unit of heparin into a unit of α-L-galacturonic acid, and related reactions.  Carbohydr Res. 1990;  200 437-447
• 25 Mourier P AJ, Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases.  Anal Biochem. 2004;  332 299-313
• 26 Hricovini M, Guerrini M, Torri G et al.. Conformational analysis of heparin epoxide in aqueous solution. An NMR relaxation study.  Carbohydr Res. 1995;  277 11-23
• 27 Cipolla L, Nicotra F, Lay L et al.. Synthesis of the disaccharides methyl 4-O-(2′/3′-O-sulfo-beta-D-glucopyranosyluronic-acid)-2-amino-2-deoxy-alpha-D glucopyranoside disodium salts, related to heparin biosynthesis.  Glycoconj J. 1996;  13 995-1003
• 28 Casu B, Torri G. Structural characterization of low molecular weight heparins.  Semin Thromb Hemost. 1999;  25(suppl 3) 17-25
• 29 Fareed J, Ma Q, Florian M et al.. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.  Semin Thromb Hemost. 2004;  30(suppl 1) 89-104
• 30 Shriver Z, Sundaram M, Venkataraman G et al.. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin.  Proc Natl Acad Sci USA. 2000;  97 10365-10370
• 31 Iacomini M, Casu B, Guerrini M et al.. Linkage region sequences of heparins and heparan sulfates. Detection and quantification by NMR spectroscopy.  Anal Biochem. 1999;  274 50-58
• 32 Desai U R, Linhardt R J. Molecular weight of heparin using ¹³C nuclear magnetic resonance spectroscopy.  J Pharm Sci. 1995;  84 212-215
• 33 Bertini S, Bisio A, Torri G et al.. Molecular weight determination of heparin and dermatansulfate by size exclusion chromatography with a triple detector array.  Biomacromolecules. 2005;  6 168-173